Nothing but NET: A review of norepinephrine transporter expression and efficacy of (131)I-mIBG therapy

Neuroblastoma is unique amongst common pediatric cancers for its expression of the norepinephrine transporter (NET), enabling tumor-selective imaging and therapy with radioactive analogues of norepinephrine. The majority of neuroblastoma tumors are avid for (123)I-metaiodobenzaguanidine (mIBG) on im...

Descripción completa

Detalles Bibliográficos
Autores principales: Streby, Keri A, Shah, Nilay, Ranalli, Mark A, Kunkler, Anne, Cripe, Timothy P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237663/
https://www.ncbi.nlm.nih.gov/pubmed/25175627
http://dx.doi.org/10.1002/pbc.25200
Descripción
Sumario:Neuroblastoma is unique amongst common pediatric cancers for its expression of the norepinephrine transporter (NET), enabling tumor-selective imaging and therapy with radioactive analogues of norepinephrine. The majority of neuroblastoma tumors are avid for (123)I-metaiodobenzaguanidine (mIBG) on imaging, yet the therapeutic response to (131)I-mIBG is only 30% in clinical trials, and off-target effects cause short- and long-term morbidity. We review the contemporary understanding of the tumor-selective uptake, retention, and efflux of meta-iodobenzylguanidine (mIBG) and strategies currently in development for improving its efficacy. Combination treatment strategies aimed at enhancing NET are likely necessary to reach the full potential of (131)I-mIBG therapy.

Ejemplares similares